Glenmark Pharma launches antidiabetic injectable
India Business News: Glenmark Pharmaceuticals has launched the first biosimilar of the popular anti-diabetic drug, Liraglutide in India. The drug, marketed as Lirafit, is
Source: indiatimes.com
Stay updated with breaking news from Icmr Indiab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
India Business News: Glenmark Pharmaceuticals has launched the first biosimilar of the popular anti-diabetic drug, Liraglutide in India. The drug, marketed as Lirafit, is
Type 2 diabetes is caused by a combination of genetic and lifestyle factors, including being overweight or obese, having a sedentary lifestyle, and consuming a diet high in sugar and processed foods.
Around 60 to 75 percent of our total calorie intake is in the form of carbohydrates and only 10 percent comprises proteins.